Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Cancer Immunol Immunother. 2018 Jun 5. doi: 10.1007/s00262-018-2183-3. [Epub ahead of print]

PMID:
29872898
2.

Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures.

Rodrigues RM, Kollipara L, Chaudhari U, Sachinidis A, Zahedi RP, Sickmann A, Kopp-Schneider A, Jiang X, Keun H, Hengstler J, Oorts M, Annaert P, Hoeben E, Gijbels E, De Kock J, Vanhaecke T, Rogiers V, Vinken M.

Arch Toxicol. 2018 May 14. doi: 10.1007/s00204-018-2214-z. [Epub ahead of print]

PMID:
29761207
3.

Exploiting the potential of unlabeled endoscopic video data with self-supervised learning.

Ross T, Zimmerer D, Vemuri A, Isensee F, Wiesenfarth M, Bodenstedt S, Both F, Kessler P, Wagner M, Müller B, Kenngott H, Speidel S, Kopp-Schneider A, Maier-Hein K, Maier-Hein L.

Int J Comput Assist Radiol Surg. 2018 Jun;13(6):925-933. doi: 10.1007/s11548-018-1772-0. Epub 2018 Apr 27.

PMID:
29704196
4.

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.

Sachpekidis C, Goldschmidt H, Kopka K, Kopp-Schneider A, Dimitrakopoulou-Strauss A.

EJNMMI Res. 2018 Apr 10;8(1):28. doi: 10.1186/s13550-018-0383-7.

5.

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24.

PMID:
29478079
6.

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912. doi: 10.1007/s00259-018-3936-0. Epub 2018 Jan 23.

PMID:
29362859
7.

Multiple-rater kappas for binary data: Models and interpretation.

Stoyan D, Pommerening A, Hummel M, Kopp-Schneider A.

Biom J. 2018 Mar;60(2):381-394. doi: 10.1002/bimj.201600267. Epub 2017 Dec 27.

PMID:
29280179
8.

Clustering of samples and variables with mixed-type data.

Hummel M, Edelmann D, Kopp-Schneider A.

PLoS One. 2017 Nov 28;12(11):e0188274. doi: 10.1371/journal.pone.0188274. eCollection 2017.

9.

Parametric modeling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology.

Holland-Letz T, Gunkel N, Amtmann E, Kopp-Schneider A.

J Biopharm Stat. 2018;28(4):763-777. doi: 10.1080/10543406.2017.1397005. Epub 2017 Nov 27.

PMID:
29173022
10.

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. doi: 10.1007/s00259-017-3870-6. Epub 2017 Nov 10.

PMID:
29124281
11.

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.

Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC.

Oncotarget. 2017 Jun 27;8(44):76029-76043. doi: 10.18632/oncotarget.18635. eCollection 2017 Sep 29.

12.

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).

Kischkel FC, Meyer C, Eich J, Nassir M, Mentze M, Braicu I, Kopp-Schneider A, Sehouli J.

J Ovarian Res. 2017 Oct 27;10(1):72. doi: 10.1186/s13048-017-0365-9.

13.

The European water-based environmental quality standard for pentachlorophenol is NOT protective of benthic organisms.

Bettinetti R, Kopp-Schneider A, Vignati DAL.

Sci Total Environ. 2018 Feb 1;613-614:39-45. doi: 10.1016/j.scitotenv.2017.09.055. Epub 2017 Sep 26.

PMID:
28898810
14.

Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.

Habermehl C, Benner A, Kopp-Schneider A.

Biom J. 2018 Mar;60(2):275-287. doi: 10.1002/bimj.201600226. Epub 2017 Aug 1.

PMID:
28762532
15.

Prediction accuracy and variable selection for penalized cause-specific hazards models.

Saadati M, Beyersmann J, Kopp-Schneider A, Benner A.

Biom J. 2018 Mar;60(2):288-306. doi: 10.1002/bimj.201600242. Epub 2017 Aug 1.

PMID:
28762523
16.

Maximum intensity breast diffusion MRI for BI-RADS 4 lesions detected on X-ray mammography.

Bickelhaupt S, Paech D, Laun FB, Steudle F, Kuder TA, Mlynarska A, Bach M, Lederer W, Teiner S, Schneider S, Ladd ME, Daniel H, Stieber A, Kopp-Schneider A, Delorme S, Schlemmer HP.

Clin Radiol. 2017 Oct;72(10):900.e1-900.e8. doi: 10.1016/j.crad.2017.05.017. Epub 2017 Jul 4.

PMID:
28687167
17.

Dissecting and modeling the emergent murine TEC compartment during ontogeny.

Brunk F, Michel C, Holland-Letz T, Slynko A, Kopp-Schneider A, Kyewski B, Pinto S.

Eur J Immunol. 2017 Jul;47(7):1153-1159. doi: 10.1002/eji.201747006. Epub 2017 May 22.

PMID:
28439878
18.

New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples.

Kischkel FC, Eich J, Meyer CI, Weidemüller P, Krapfl J, Yassin-Kelepir R, Job L, Fraefel M, Braicu I, Kopp-Schneider A, Sehouli J, De Wilde RL.

PeerJ. 2017 Mar 2;5:e3030. doi: 10.7717/peerj.3030. eCollection 2017.

19.

Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.

Beisel C, Benner A, Kunz C, Kopp-Schneider A.

Biom J. 2017 May;59(3):511-530. doi: 10.1002/bimj.201600047. Epub 2017 Mar 6.

PMID:
28263395
20.

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O, Eggert A, Fischer M, Deubzer HE.

Cell Death Dis. 2017 Mar 2;8(3):e2635. doi: 10.1038/cddis.2017.49.

Supplemental Content

Loading ...
Support Center